Leflunomide: Dermatologic perspective

Journal of Dermatological Treatment

Volumn 24, Issue 2, 2013, Pages 89-95

  Sehgal, Virendra N ^a   Verma, Prashant ^b  

^a Sehgal Nursing Home   (India)

^b UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Atopic dermatitis; Bullous pemphigoid; Dermatomyositis; Leflunomide in dermatology; Primary Sj gren's syndrome; Psoriasis; Psoriatic arthritis; Sarcoidosis; Systemic lupus erythematosus; Systemic sclerosis; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; COLESTYRAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FLUCLOXACILLIN; FLUOCINONIDE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALOPECIA; ATOPIC DERMATITIS; BULLOUS PEMPHIGOID; DERMATOLOGY; DERMATOMYOSITIS; DIARRHEA; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; HUMAN; HYPERTENSION; INTERSTITIAL PNEUMONIA; LABORATORY TEST; LOADING DRUG DOSE; MAINTENANCE THERAPY; NAUSEA; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIDE EFFECT; SJOEGREN SYNDROME; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; VASCULITIS; VOMITING; WEGENER GRANULOMATOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; DERMATOLOGIC AGENTS; ENZYME INHIBITORS; HUMANS; ISOXAZOLES; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; SKIN DISEASES;

EID: 84875331454     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.595383     Document Type: Review

References (55)

1. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593-596.
2. Silva Júnior HT, Morris RE. Leflunomide and malononitrilamides. Am J Med Sci. 1997;313:289-301. (Pubitemid 27198241)
3. HerrmannML,Schleyerbach R, KirschbaumBJ.Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology. 2000;47:273-289. (Pubitemid 30394543)
4. O'Donnell EF, Saili KS, Koch DC, Kopparapu PR, Farrer D, Bisson WH, et al. The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS One. 2010; 5:e13128.
5. Leflunomide. In: AHFS Drug Information 2003. American Society of Health-System Pharmacists- Bethesda; 2003. p. 3639-3644.
6. Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-specific manner. Br J Pharmacol. 1999;127:1589-1596. (Pubitemid 29368992)
7. Kehrer T, Blümlein K, Wozel G. Eotaxin release is suppressed by the metabolite A 77 1726 of the novel immunomodulating agent leflunomide. Eur J Allergy Clin Immunol. 2001;56:144.
8. Pfeiffer C, Kehrer T, Wozel G. Suppression of eotaxin expression and release by leflunomide's active metabolite A77 1726 is not reversed by uridine, XXIII EAACI congress, Amsterdam; 2004. p. 12-16.06.
9. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol. 2000;165:5962-5969.
10. Kale VP, Bichile LS. Leflunomide: a novel disease modifying anti-rheumatic drug. J Postgrad Med. 2004;50:154-157. (Pubitemid 39069778)
11. Agarwal SK, Narsimulu G, Handa R. Leflunomide-The Indian Experience: a multicentre assessment of its safety and effectiveness in the treatment of active rheumatoid arthritis. J Indian Rheumatol Assoc. 2002;10:30-35.
12. Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther. 2004;26:447-459. (Pubitemid 38586447)
13. Jakez-Ocampo J, Richaud-Patin Y, Simón JA, Llorente L. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint Bone Spine. 2002;69:307-311. (Pubitemid 34654366)
14. Frieling U, Luger TA. Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases. Clin Exp Dermatol. 2002;27:562-570. (Pubitemid 35463872)
15. van Riel PL, Smolen JS, Emery P, Kalden JR, Dougados M, Strand CV, et al. Leflunomide: a manageable safety profile. J Rheumatol Suppl. 2004;71:21-24. (Pubitemid 38703144)
16. van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers Jr. Leflunomide for the treatment of rheumatoidarthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf. 2004;27:345-352. (Pubitemid 38530464)
17. Holm EA, Balslev E, Jemec GB. Vasculitis occurring during leflunomide therapy. Dermatology. 2001;203:258-259. (Pubitemid 33035987)
18. Chan AT, Bradlow A, McNally J. Leflunomide induced vasculitisea dose-response relationship. Rheumatology. 2003;42:492-493. (Pubitemid 36367550)
19. Chan J, Sanders DC, Du L, Pillans PI. Leflunomideassociated pancytopenia with or without methotrexate. Ann Pharmacother. 2004;38:1206-1211.
20. Bharadwaj A, Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology. 2004;43:934.
21. Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther. 2004;75: 580-585. (Pubitemid 38746609)
22. Carulli MT, Davies UM. Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology. 2002;41:952-953.
23. Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol. 2005;32:1160-1163. (Pubitemid 40828105)
24. Kamata Y, Nara H, Kamimura T, Haneda K, Iwamoto M, Masuyama J, et al. Rheumatoid arthritis complicated with acute intersitial pneumonia induced by leflunomide as an adverse reaction. Intern Med. 2004;43:1201-1204. (Pubitemid 40074162)
25. Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis. 2002;61:850-851.
26. Fischer TW, Bauer HI, Graefe T, Barta U, Elsner P. Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology. 2003; 207:386-389. (Pubitemid 37505788)
27. Kerr OA, Murray CS, Tidman MJ. Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol. 2004;29:319-320. (Pubitemid 38658486)
28. Goeb V, Berhelot JM, Joly P, Mejjad O, de Quartrebarbes J, Reynaud-Hautin C, et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology. 2005;44: 823-824. (Pubitemid 41487219)
29. Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis. 2005;64:153-155. (Pubitemid 40075297)
30. Behrens F, Koehm M, Burkhardt H. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. Curr Opin Rheumatol. 2011;23:282-287.
31. Arava (leflunomide) Prescribing information as of September 2003. Aventis Pharmaceuticals, Inc. Kansas City, MO 64137.
32. Veeranna S, Jayadev B, Kushalappa PA. Severe cutaneous adverse drug reaction to leflunomide: a report of 5 cases. Indian J Dermatol Venereol Leprol. 2006;72:286-289.
33. Annonymous. National health services (NHS), Shared Care Guidelines. Leflunomide - monitoring protocol, updated on January 28th, 2011. England.
34. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004; 50:1939-1950. (Pubitemid 38725106)
35. Malesci D, Tirri R, Buono R, La Montagna G. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Clin Exp Rheumatol. 2007;25:881-884. (Pubitemid 351166441)
36. Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol. 2001;7: 366-370. (Pubitemid 33151098)
37. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis. 2008;67:855-859. (Pubitemid 351829388)
38. Tlacuilo-Parra JA, Guevara-Gutiérrez E, Rodríguez- Castellanos MA, Ornelas-Aguirre JM, Barba-Gómez JF, Salazar-Páramo M. Leflunomide in the treatment of psoriasis: results of a phase II open trial. Br J Dermatol. 2004;150: 970-976. (Pubitemid 38903531)
39. Schmitt J, Wozel G, Pfeiffer C. Leflunomide as a novel treatment option in severe atopic dermatitis. Br J Dermatol. 2004;150:1182-1185. (Pubitemid 38932290)
40. Wozel G, Vitéz L, Pfeiffer C. Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data. Dermatol Online J. 2006;12:6.
41. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Doubleblind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus. 2004; 13:601-604. (Pubitemid 39145490)
42. Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus. 2001;10:480-483. (Pubitemid 32675047)
43. Bremer JP, Ullrich S, Laudien M, Gross WL, Lamprecht P. Methotrexate plus leflunomide for the treatment of relapsing Wegener's granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol. 2010;28:67-71.
44. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology. 2007;46:1087-1091. (Pubitemid 47050609)
45. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold- Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology. 2004;43:315-320. (Pubitemid 38313180)
46. Henes JC, Fritz J, Koch S, Klein R, Horger M, Risler T, et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis- additive effects of a maintenance treatment with leflunomide. Clin Rheumatol. 2007;26:1711-1715.
47. van Woerkom JM, Kruize AA, Geenen R, van Roon EN, Goldschmeding R, Verstappen SM, et al. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66:1026-1032. (Pubitemid 47122314)
48. Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol. 2000;136:1204-1205.
49. Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol. 2008;58:403-406.
50. Majithia V, Sanders S, Harisdangkul V, Wilson JG. Successful treatment of sarcoidosis with leflunomide. Rheumatology. 2003;42:700-702.
51. Sebastiani M, Giuggioli D, Vesprini E, Caruso A, Ferri C. Successful treatment with leflunomide of arthritis in systemic sclerosis patients. Rheumatology. 2006;45:1175-1176. (Pubitemid 44542117)
52. Scarpato S, Tirri E. Successful treatment of SAPHO syndrome with leflunomide. Report of two cases. Clin Exp Rheumatol. 2005;23:731. (Pubitemid 41300731)
53. Reich K, Hummel KM, Beckmann I, Mössner R, Neumann C. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol. 2002;146:335-336. (Pubitemid 34264415)
54. Melwani PM, Peñate Y, Guillermo N, Soler E, Hernández- Machín B, Borrego L. Leflunomide in the treatment of palmoplantar pustulosis. Arch Dermatol. 2009;145: 1224-1226.
55. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93:198-208.